Hangzhou Muyuan Biomedical Technology Co., Ltd.

Primary Objective: To compare the extent and rate of absorption of emedastine fumarate extended-release capsules (2 mg) supplied by Muyuan (Anhui) Pharmaceutical Co., Ltd. and emedastine fumarate extended-release capsules (trade name: Remicut®; 2 mg) licensed by Kowa Co., Ltd. in healthy Chinese subjects under fasting and fed conditions. Secondary Objective: To evaluate the safety of emedastine fumarate extended-release capsules (2 mg) supplied by Muyuan (Anhui) Pharmaceutical Co., Ltd. and emedastine fumarate extended-release capsules (trade name: Remicut®; 2 mg) licensed by Kowa Co., Ltd. in healthy study participants under fasting and fed conditions.

Main study objectives To study the pharmacokinetics of the test preparation Cefuroxime Hydrochloride Granules (Specification: 50mg (calculated as C17H19N5O6S2), provided by Muyuan (Anhui) Pharmaceutical Co., Ltd.) and the reference preparation Cefuroxime Hydrochloride Granules (Specification: 10% (1g contains 100mg hydrochloride hydrate, 50mg/bag)), trade name: Flomox®, certified by Shionogi Pharmaceutical Co., Ltd.) in healthy adult subjects in the fasting and fed state, and to evaluate the bioequivalence of the two preparations in the fasting and fed state. Secondary study objectives To evaluate the safety of the test preparation Cefuroxime Hydrochloride Granules and the reference preparation Cefuroxime Hydrochloride Granules (Flomox®) in the fasting and fed state in healthy Chinese subjects.

This study aims to study the pharmacokinetic characteristics of teprenone capsules (50 mg) provided by Hangzhou Muyuan Biotechnology Co., Ltd. after single fasting and postprandial oral administration; using teprenone capsules (50 mg) produced by Eisai (China) Pharmaceutical Co., Ltd. as the reference preparation, compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations, and evaluate the bioequivalence of the two preparations in humans.